Salubrent has officially launched the first of many planned state-of-the-art analytical labs, which will be strategically located around the country to flexibly address the changing needs of today’s pharmaceutical and biotech companies. With an emphasis on quality, innovation, and responsiveness, our scientific team will provide the testing stability studies, and analytical methods required for the successful development of the next generation of therapeutics.


SALUBRENT NOW OFFERS STATE-OF-THE-ART ANALYTICAL TESTING SERVICES
AND SOON WE’LL BE OFFERING FLEXIBLE, ASEPTIC FILL & FINISH FORMULATION AND MANUFACTURING
Beginning in 2022, Salubrent will launch a new technology-focused contract development and manufacturing organization (CDMO) dedicated to flexible, state-of-the-art aseptic fill & finish solutions. As a full-service CDMO, Salubrent will focus on serving clinical and commercial stage pharmaceutical and biotech companies in need of flexible batch production of sterile injectable products using the latest in fill-finish technologies.
Salubrent represents the future of flexible fill & finish development and manufacturing.
Terry NovakPresident & CEO, Salubrent Pharma Solutions
We are a technology-enabled CDMO offering comprehensive analytical services to pharma and biotech companies. Salubrent also has the quality and regulatory expertise to successfully bring your product to the clinic, and beyond.
ANALYTICAL
SERVICES
We are now offering comprehensive analytical services, staffed with experience scientists who will use a flexible approach to meet your specific analytical needs. We will work closely with you to develop and maintain unique methodologies to optimize the stability and effectiveness of your drug candidate from scale-up to commercial manufacturing.
LEARN MORE »
LEARN MORE »
FORMULATION
DEVELOPMENT
(BEGINNING IN 2022)
Whether small or large molecule, Salubrent offers flexible solutions for your small commercial batch needs, moving you through the development process quickly and efficiently without the need of a reiterative validation process. And through our US-based API partnerships, we can ensure the security of your supply.
LEARN MORE »
LEARN MORE »
MANUFACTURING
SERVICES
(BEGINNING IN 2022)
We expect our fill & finish services to be operational during 2022 at our state-of-the-art purpose-built facility using innovative robotic manufacturing technologies that will provide flexible drug delivery solutions in formats including single-use consumables and ready-to-use, pre-sterilized containers and closures.
LEARN MORE »
LEARN MORE »
We delight our customers with excellent customer service, leading-edge technologies, and our deep knowledge of aseptic fill & finish solutions. Reach out and learn more.
Latest News

Salubrent: GCHS & GC/MS Capabilities Handle Complex Projects
Special Feature from the annual Drug Development & Delivery report: Analytical Testing Trends in 2022 “Salubrent Pharma Solutions is a recently formed CDMO focused on supporting the shift toward biologics and personalized medicines, where small batch fill and finish services,…

Harish Dave, MB, ChB, MBA, Joins Salubrent Board
KANNAPOLIS, N.C., Jan. 6, 2022-- Salubrent announces the addition of Dr. Harish Dave to its Board of Directors. Dr. Dave brings more than 35 years of experience in the sciences, academia, finance and pharma industry, including extensive work with the…